A meta-analysis of six comparative studies involving 6,874 patients with resected stage I pancreatic cancer revealed that adjuvant chemotherapy is associated with significantly higher overall survival and 2-year survival rates compared to surgery alone. However, there was no statistically significant difference in 1-year, 3-year, or 5-year survival rates. This study suggests that adjuvant chemotherapy may confer survival benefits for stage I pancreatic cancer, but randomized control trials are needed to further validate these findings.
Review by Evans D, Ghassemi N (…) Athwal TS et 5 al. in BMC Surg
Copyright © 2023 Elsevier Inc. All rights reserved.